Study of DCR-PHXC-101 in Normal Healthy Volunteers and Patients With Primary Hyperoxaluria

NCT03392896 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

43

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Hyperoxaluria

Interventions

DRUG: DCR-PHXC
DRUG: Placebo

Sponsor

Dicerna Pharmaceuticals, Inc., a Novo Nordisk company